The Effect and Mechanism of Electroacupuncture on Acute Chemotherapy-induced Nausea and Vomiting
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Anticipé)
Inscription
Phase
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Jin, Doctor
- E-mail: king-jlm@163.com
Lieux d'étude
-
-
Shaanxi
-
Xi'an, Shaanxi, Chine, 710032
- Recrutement
- Xijing Hospital
-
Contact:
- Yang
- Numéro de téléphone: 86(029)-84775343
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- First diagnosed stage Ⅲ-Ⅳ lung cancer patients on cisplatin chemotherapy;
- Right-handed and aged 18 to 75 years;
- Karnosky performance status (KPS) ≥ 70;
- Life expectancy ≥ 6 months.
Exclusion Criteria:
- Had brain metastases or other concurrent life-threatening diseases;
- Nausea and/or vomiting were present 24h before chemotherapy treatment;
- Suffered from or had a history of gastrointestinal diseases;
- Had a history of head trauma, serious neurological or psychiatric disorders;
- Participating in other clinical trials currently;
- Had any contraindication to exposure to a high magnetic field or receive acupuncture
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Acupuncture 1
In this group, patients separately received twice electroacupuncture at bilateral PC6 acupoint before and after Cisplatin administration on the first day of chemotherapy.
|
The needles used were Huatuo brand (Suzhou, China) sterile disposable stainless steel filiform; needles sized 0.25*25 mm.
After disinfection, needles were inserted 0.5 to 0.8 inches into the skin and were manipulated manually to obtain Deqi.
An electric stimulator (Huatuo SDZ-V, Suzhou, China) was connected to the needles and delivered a constant-current, 0.2-ms, density-wave, stimulus of 2 to 10-Hz frequency, level of intensity was as much as tolerable, but not painful to the subjects.
The needles were left for 30 minutes and then removed.
|
|
Expérimental: Acupuncture 2
In this group, patients separately received twice electroacupuncture at bilateral PC6 and RN12 acupoints before and after Cisplatin administration on the first day of chemotherapy.
|
The needles used were Huatuo brand (Suzhou, China) sterile disposable stainless steel filiform; needles sized 0.25*25 mm.
After disinfection, needles were inserted 0.5 to 0.8 inches into the skin and were manipulated manually to obtain Deqi.
An electric stimulator (Huatuo SDZ-V, Suzhou, China) was connected to the needles and delivered a constant-current, 0.2-ms, density-wave, stimulus of 2 to 10-Hz frequency, level of intensity was as much as tolerable, but not painful to the subjects.
The needles were left for 30 minutes and then removed.
|
|
Comparateur factice: Sham acupuncture
In this group, patients separately received twice electroacupuncture at bilateral nonacupuncture point (S1 located at lateral of flexor carpi radialis, 2 cun above the wrist.
S2 located at 3 cun right side of RN12) before and after Cisplatin administration on the first day of chemotherapy.
|
The needles used were Huatuo brand (Suzhou, China) sterile disposable stainless steel filiform; needles sized 0.25*25 mm.
After disinfection, needles were inserted 0.5 to 0.8 inches into the skin and were manipulated manually to obtain Deqi.
An electric stimulator (Huatuo SDZ-V, Suzhou, China) was connected to the needles and delivered a constant-current, 0.2-ms, density-wave, stimulus of 2 to 10-Hz frequency, level of intensity was as much as tolerable, but not painful to the subjects.
The needles were left for 30 minutes and then removed.
|
|
Aucune intervention: Waitinglist control
In this group, patients received no electroacupuncture
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
The scores of Rhodes Index of Nausea, Vomiting and Retching.
Délai: 24 hours
|
24 hours
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Content of 5-hiaa in urine
Délai: 12 hours
|
12 hours
|
|
Heart Rate Variability
Délai: 1 hour
|
1 hour
|
|
Tachygastria percentage
Délai: 1 hour
|
1 hour
|
|
Dosage of antiemetic drugs
Délai: 24 hours
|
24 hours
|
Autres mesures de résultats
Autres mesures de résultats
Mesure des résultats |
Délai |
|---|---|
|
Neuroimaging data
Délai: 24 hours
|
24 hours
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement primaire
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- 2014CB543203
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .